MLchartDataset catalogue

anti-PD-1/anti-CTLA-4/anti-VEGF trispecific antibody HC010

Term · Oncology and biomedicine · MLC-T-ONC-010971

A trispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration, anti-PD-1/anti-CTLA-4/anti-VEGF trispecific antibody HC010 simultaneously targets, binds to and blocks PD-1 and CTLA-4 expressed on tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment (TME), thereby inhibiting the PD-1- and CTLA-4-mediated downregulation of T-cell activation and proliferation. This restores immune function and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of HC010 to VEGF prevents binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis. Both PD-1 and CTLA-4 negatively regulate the activation and effector functions of T cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD-1 and CTLA-4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. VEGF is overexpressed in a variety of cancers and is associated with increased invasiveness and decreased survival.

Table 1. Record
IdentifierMLC-T-ONC-010971
FieldOncology and biomedicine
SynonymsPD-1/CTLA-4/VEGF trispecific antibody HC010
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010971",
  "term": "anti-PD-1/anti-CTLA-4/anti-VEGF trispecific antibody HC010",
  "field": "Oncology and biomedicine",
  "definition": "A trispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration, anti-PD-1/anti-CTLA-4/anti-VEGF trispecific antibody HC010 simultaneously targets, binds to and blocks PD-1 and CTLA-4 expressed on tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment (TME), thereby inhibiting the PD-1- and CTLA-4-mediated downregulation of T-cell activation and proliferation. This restores immune function and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of HC010 to VEGF prevents binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis. Both PD-1 and CTLA-4 negatively regulate the activation and effector functions of T cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD-1 and CTLA-4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. VEGF is overexpressed in a variety of cancers and is associated with increased invasiveness and decreased survival.",
  "synonyms": [
    "PD-1/CTLA-4/VEGF trispecific antibody HC010"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-pd-1-anti-ctla-4-anti-vegf-trispecific-antibody-hc010/"
}

Record 2,101 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.